China is expected to develop the first molecular targeted drug for psoriasis

Professor Wang Honglin, School of medicine, Shanghai Jiaotong University, developed a small molecule natural active compound named akba on the basis of cooperation with researchers from Ulm University, Germany The compound is expected to become a new drug for the treatment of psoriasis Relevant research papers have recently been published in the international authoritative journal of immunology According to the review of nature rheumatology, akba may be used to treat other chronic inflammatory diseases associated with NF kappaB Psoriasis (commonly known as psoriasis) is a common chronic skin disease, which incidence rate is about 0.123% Because of the large population, psoriasis patients are a large group in China In clinic, psoriasis is considered as an autoimmune disease mediated by CD4 positive T cells However, more and more studies show that macrophages are important sources of many proinflammatory cytokines in the pathogenesis of psoriasis It has been thought that the pathogenesis of psoriasis is closely related to the activation of IL-23 and NF kappaB In the research, Professor Wang Honglin and others developed a natural active small molecule akba, which can inhibit the activation of NF kappaB, and then used liposome as a targeted drug delivery carrier to enter macrophages to achieve the effect of molecular targeted therapy on psoriasis mice Akba is a kind of natural herbal active extract, which has strong targeting, wide source of raw materials and low price It can improve the symptoms of psoriasis and reduce the pain of patients when it is made into ointment, oral tablet or injection.